Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Walgreen Company (WAG), AmerisourceBergen Corp. (ABC), Express Scripts Holding Company (ESRX), Humana Inc. (HUM): 3 Health Care Stories You Probably Missed

This year, health care stocks are leading the S&P 500 for the first time in well over a decade. It’s a vote of confidence in a landscape that’s changing around the Affordable Care Act. While the more speculative biotech industry gets attention from The Fool elsewhere, here’s a look at the top stories from the less-sung parts of health care.

Walgreen Company (WAG)

As we begin the last mini-week of the month, the news was as mixed as the Northeast weather. A drug store made a distribution power play. An insurer fell on Medicare nervousness. And a health care information technology company branched out with a new acquisition.

Walgreen Company (NYSE:WAG) announced that it was signing a 10-year contract with drug distributor AmerisourceBergen Corp. (NYSE:ABC), and had an option of buying a 7% stake. That left its former primary distributor Cardinal Health out in the cold, and shares dropped accordingly. The move will increase the drugstore chain’s prices on both branded and generic drugs, which should lead to higher profit margins.

Also coming along for the ride was European chain Alliance Boots, which Walgreen’s partially acquired last year. Combined, the moves will improve Walgreen Company (NYSE:WAG)’s market position and perhaps its bargaining power with pharmacy benefit managers such as Express Scripts Holding Company (NASDAQ:ESRX).

Turning towards the health plan side of things…

Humana Inc. (NYSE:HUM) closed the week down almost 4% after a Susquehanna analyst lowered the company’s rating from “Positive” to “Neutral,” citing concerns with potential Medicare Advantage rate cuts. The company’s shares had dropped 10% last month when the Centers for Medicare and Medicaid Services’ announced its proposed rates, which could lead to losses of $11 billion across Advantage providers. Humana Inc. (NYSE:HUM) is one of the segment leaders, with 2 million Advantage customers. Expect further volatility in health care plans this week since the final rate decision is due next Monday.

And rounding out the week’s review, Cerner (NASDAQ:CERN) Corporation acquired Labotix Automation, which provides automation solutions in clinical testing environments. The details weren’t disclosed. It’s the latest in a string of acquisitions for Cerner, which is diversifying its business as the spending boost from the 2009 stimulus winds down and the ACA kicks in. Cerner finished the week up less than 1%, but this is a stock meant for the long haul.

The article 3 Health Care Stories You Probably Missed originally appeared on

Fool contributor Brandy Betz has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.